| Zhu, Feng |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 258 | RoW | TQC2731 injection, TQC2731 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/26 | 09/27 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006) |
|
|
| Completed | N/A | 1000 | RoW | bone scintigraphy | Fudan University | Bone Metastases | 11/21 | 11/22 | | |
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19 |
|
|
| Recruiting | N/A | 5815 | RoW | Glucocorticoid, dexamethasone, prednisone, methylprednisolone | Huashan Hospital | COVID-19 | 05/24 | 12/24 | | |
NCT05850585: A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia |
|
|
| Not yet recruiting | N/A | 100 | NA | Fecal microbiota transplantation(FMT), Placebo | First Affiliated Hospital Xi'an Jiaotong University | Schizophrenia | 12/25 | 12/26 | | |
NCT05850572: A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression |
|
|
| Not yet recruiting | N/A | 100 | NA | Fecal microbiota transplantation(FMT), Placebo | First Affiliated Hospital Xi'an Jiaotong University | Depression | 12/25 | 12/26 | | |
| Jiang, Jianzhong |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
| Ma, Xiuqin |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 258 | RoW | TQC2731 injection, TQC2731 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/26 | 09/27 | | |
